A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

May 17, 2011

New HIV Vaccine Candidate Might Offer Success Where Previous Versions Failed

A new type of vaccine has resulted in successful control of SIV (simian immunodeficiency virus), the monkey version of HIV, in about half the monkeys who received the vaccine and were then later exposed to the virus. These findings, published online May 11 in the journal Nature, might offer a new avenue for vaccine research.

In the natural course of HIV infection, a person’s immune system often takes weeks after initial exposure to respond in a meaningful way to the virus, and though most people are able to naturally bring down HIV levels substantially, their immune systems never fully control it. Eventually, if people don’t receive combination antiretroviral (ARV) therapy, they develop AIDS and die.

Nearly every effort to find a successful vaccine to prevent HIV infection has failed because of the virus’s ability to change itself and avoid immune control. Efforts to provoke the immune system to better control HIV if a person does become infected—rather than protecting from infection in the first place—have also failed.

Aside from the difficulty they’ve encountered in provoking the right immune response with the right pieces of HIV proteins, experts have also had a hard time finding a delivery vehicle for those proteins—one that will trigger a strong and long-lasting immune response without causing harm.

Vaccine researcher Louis Picker, MD, from Oregon Health & Science University (OHSU) in Portland, has been focused on this task for about a decade. He and his team have chosen the cytomegalovirus (CMV) as their delivery vehicle, referred to in scientific circles as a vector. CMV is widely spread—most people have been infected with this close relative of the herpes virus—and the effects of CMV tend to be minimal in the young and healthy. CMV has been tied in some studies to depletion and damage to the immune system in elderly people and some suspect that the same is likely to be true in people with HIV even when their CD4 counts are high.

In this experiment, Picker’s team vaccinated a group of rhesus macaques with an SIV vaccine that was delivered with the CMV vector; researchers then subsequently infected the monkeys with SIV. The team also infected a group of monkeys who weren’t vaccinated. Both groups were followed over time.

Picker found that while all of the monkeys who got no vaccine developed AIDS-like symptoms and died, only half the vaccinated monkeys became ill. In those who remained healthy, only tiny bits of SIV could be found in their blood and tissue, and some of the monkeys appeared to be on the way to eradicating the virus almost completely.

It is a long way to go from studies in monkeys to studies in humans, and much remains uncertain. Nevertheless, Picker is optimistic.

“The next step in vaccine development is to test the vaccine candidate in clinical trials in humans,” he stated in a release from OHSU.

“For a human vaccine the CMV vector would be weakened sufficiently so that it does not cause illness, but will still protect against HIV,” he concluded.

Search: Cytomegalovirus, CMV, herpes, vaccine, vector, simian immunodeficiency virus, SIV, rhesus macaques, Louis Picker, Oregon Health & Science University, Portland


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (3 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    adoniz89
    san dimas
    California


    Loveladyd
    Washington
    DC


    Heartland4now
    Tacoma
    Washington


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.